ARCHIVES

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

Advisors Clear Herceptin; Find Tamoxifen Indicated For “Short Term Risk Reduction”

September 11, 1998

Ethics Commission To Continue Consideration Of Compensation For Injured Research Subjects

June 20, 1980

ICCCR Participants Honor Cullen, Blast Tobacco Industry

March 15, 1991

Almost Half of Faculty on IRBs Have Industry Ties, Study Finds

September 26, 2003

Technology Transfer Is Theme For 1990s, Broder Tells Writers; Laszio Offers Predictions On Treatment Advances

April 6, 1990

Phase III Trial: Panobinostat Increases PFS by Four Months

September 26, 2014